Vendor, Galveston, TX
Chrysalis Biotherapeutics, Inc.
UEI XW1VFGGRLDW3, CAGE 5DAY4
1 award and -$11,857,903 obligated between July 25, 2025 and July 25, 2025, 100% under full and open competition, against 1.0 offers on average where reported.
Sells to
Awarding agencies by dollars.
| Office of Assistant Secretary for Preparedness and Response | -$11,857,903 |
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | -$11,857,903 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75A50119C00016Definitive Contract, July 25, 2025, Full and Open Competition, 1 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | De-Obligate Remaining Funds and Closeout the Contract in Its Entirety.NAICS 541714, PSC AN13 | -$11,857,903 |
- Places of performance
- Texas
- Product and service codes
- AN13 Health R&D Services; Health Care Services; Experimental Development
- Transactions
- 1 across 1 awards